Enterprise Value
1.825B
Cash
4.754M
Avg Qtr Burn
-2.61M
Short % of Float
0.02%
Insider Ownership
0.00%
Institutional Own.
18.49%
Qtr Updated
09/30/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2 Data readout | ||
Dipraglurant (mGlu5 NAM) Details Levodopa-induced dyskinesia associated with Parkinson’s disease | Failed Discontinued | |
Dipraglurant (mGlu5 NAM) Details Dystonia (Blepharospasm) | Failed Discontinued |